OBR Daily Commentary

forumImage

Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer

(NASDAQ) Oct 5, 2018 - Progenics Pharmaceuticals, Inc., an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced data from its OSPREY 2301 Study of PyLTM (18F-DCFPyL).

Read Article arrow

Tomasz M. Beer, MD, FACP (Posted: October 08, 2018)

quotesThe results of OSPREY 2301 will need to be confirmed, but look quite promising and address one of the important needs in the field of prostate cancer. Improved imaging is essential to improve treatment decisions in early stage prostate cancer, and this approach may finally move us forward in this difficult area where little has changed in decades.quotes

Add Comment 1 Comment
forumImage

Combination Therapy of Prostatectomy Plus Radiotherapy May Improve Survival in Patients with Locally Advanced Prostate Cancer

(Jefferson Health) Sept 25, 2018 - A comparison of two of the most common combination therapies for locally advanced prostate cancer show the more aggressive option is linked with a higher rate of survival.

Read Article arrow

Tomasz M. Beer, MD, FACP (Posted: September 28, 2018)

quotesOptimal local therapy for high risk prostate cancer is not known. While this study suggest that surgery + radiation may yield improved outcomes over radiation (+hormonal therapy), population based analyses cannot provide high quality practice defining evidence. Treatment decisions were not made at random and likely incorporated a myriad of patient and tumor factors that patients and physicians consider when choosing therapy. The apparent difference is just as likely to reflect systematic patient selection bias as it is differences in the efficacy between two treatment approaches.quotes

Add Comment 1 Comment
forumImage

Dismissing Reduced Abiraterone Dose Is 'Absolutely Wrong'

(Medscape Medical News) Sept 17, 2018 - A debate has intensified about cutting the dose — and hence the cost — of the oral prostate cancer drug abiraterone acetate (Zytiga, Janssen) by taking it with food.

Read Article arrow

Tomasz M. Beer, MD, FACP (Posted: September 18, 2018)

quotesWhile there is room for a range of views, this is a situation where there must be room for clinical skill and judgment. Skilled clinical assessment and monitoring of cancer status, carried out by an expert oncologist would very likely capture the benefits of abiraterone even if dosed in an alternative fashion. Oncologists do not practice strictly "on label" in any disease. They integrate best available evidence and apply it to each individual patient's unique circumstance. There is no question that the evidence is strongest for conventional food-free dosing, but there is now sufficient evidence to have a through discussion with individual patients about the option of alternative dosing when the economic consequences of not doing so may deny the patient access to the drug altogether. quotes

Add Comment 2 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...